Trials / Completed
CompletedNCT01153269
Long-term Effectiveness and Safety in Hepatitis-co-infected Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 33 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to observe the tolerability and effectiveness of Kaletra in Human Immunodeficiency Virus/Hepatitis-B Virus and Human Immunodeficiency Virus/Hepatitis-C Virus co-infected patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lopinavir/Ritonavir (Kaletra) | 3 capsules 2xdaily or 2 tablets 2xdaily Kaletra |
Timeline
- Start date
- 2001-05-01
- Primary completion
- 2010-11-01
- Completion
- 2010-11-01
- First posted
- 2010-06-30
- Last updated
- 2011-12-19
- Results posted
- 2011-12-19
Locations
8 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01153269. Inclusion in this directory is not an endorsement.